CORT's Dazucorilant Fails to Meet Goal in Neurologic Disorder Study

Published on 12 Dec 2024 on Zacks · via Yahoo Finance

Corcept Therapeutics Incorporated CORT announced data from the phase II DAZALS study evaluating its...

Read the rest of the article

Start tracking your investments with Statfolio

Corcept Therapeutics Incorporated CORT recently announced the submission of a new drug applicatio...

Zacks · via Yahoo Finance 31 Dec 2024

We recently compiled a list of the 10 Stocks That Will Make You Rich In 2025. In this article, we...

Insider Monkey · via Yahoo Finance 25 Dec 2024

Corcept Therapeutics Incorporated CORT announced data from the phase II DAZALS study evaluating i...

Zacks · via Yahoo Finance 12 Dec 2024

Our time-tested methodologies were at work to help investors navigate the market well last week....

Zacks · via Yahoo Finance 25 Nov 2024

Shares of Corcept Therapeutics Incorporated CORT have rallied 60.7% in the past three months agai...

Zacks · via Yahoo Finance 22 Nov 2024

Corcept Therapeutics' Commercial Drug Korlym Sales Impress Despite Increased Competition, Analyst...

Benzinga · via Yahoo Finance 30 Sep 2024

Corcept Therapeutics Incorporated (NASDAQ:CORT) Q1 2024 Earnings Call Transcript May 1, 2024 Corc...

Insider Monkey via Yahoo Finance 2 May 2024

Corcept Therapeutics Incorporated CORT reported first-quarter 2024 earnings of 25 cents per share...

Zacks via Yahoo Finance 2 May 2024

Small-cap and midcap U.S. stocks are trading relatively low to historical price-to-earnings...

Market Watch 23 Apr 2024

Corcept Therapeutics (CORT) reports positive phase 3 trial results for Cushing's syndrome candida...

Seeking Alpha 22 Apr 2024